Platform

Our platform integrates artificial intelligence and synthetic biology to revolutionize the antibody design and development process. We replace the traditional methods such as hybridoma technology, phage display, and antibody libraries with our proprietary methods that are faster, cheaper, and more efficient. Here are the main steps and features of our platform:

Target identification: We identify and select the protein antigens that we want our antibody to bind to. These proteins are associated with a disease or a condition that we want to treat or prevent. We use various computational and experimental methods to find the best targets for our antibody candidates.

Epitope mapping: We determine the specific region or site on the protein antigen that our antibody will recognize and bind to. This region is called the epitope. We use advanced algorithms and databases to predict and analyze the epitopes of our target antigens. We also use a state-of-the-art protein language model that is trained on 65 million unique protein sequences. This model can extract high-quality representations from protein sequences and predict missing amino acids using the neighbouring context.

Antibody discovery: We generate a large number of antibody candidates that can potentially bind to our target epitopes. We use a deep generative model that jointly models sequences and structures of complementarity-determining regions (CDRs) based on diffusion processes and equivariant neural networks. This model can explicitly target specific antigen structures and generate antibodies at atomic resolution. It can also perform sequence-structure co-design, sequence design, structure prediction, and antibody optimization.

In-silico validation: We test and evaluate our antibody candidates in silico, which means using computer simulations and models. We use various tools such as homology modeling, protein-protein docking, and interface prediction to assess the specificity, stability, and function of our antibodies.

Synthesis of antibody using expression system: We synthesize our selected antibody candidates using biological systems such as mammalian cells. We use synthetic biology techniques to optimize the expression and production of our antibodies.

Humanization of generated antibody: We modify our antibodies to make them more compatible with the human immune system.